SCHEMBL30769043

SCHEMBL30769043

Cc1cc(N2CCC3(CCNC3)CC2)ccc1N1CCC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 6/20 0.48
CRBN Q96SW2 6/20 0.48
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
ADRB1 P08588 1/20 0.37
KHK P50053 1/20 0.37
USP2 O75604 2/20 0.37
CYP2D6 P10635 2/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
USP28 Q96RU2 1/20 0.37
SOS1 Q07889 1/20 0.37
CYP11B1 P15538 1/20 0.36
NPY2R P49146 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30769009 0.99 DDB1 (0.47) DDB1CRBNSLC6A2SLC6A4SLC6A3
SCHEMBL27039567 0.85 DDB1 (0.56) DDB1CRBNSLC6A4ADRB1KHK
Hydrochloric Acid SCHEMBL30969010 0.83 DDB1 (0.55) DDB1CRBNSLC6A4ADRB1CYP2D6
SCHEMBL30723747 0.83 CRBN (0.54) DDB1CRBNSLC6A2SLC6A4SLC6A3
SCHEMBL30778287 0.81 DDB1 (0.57) DDB1CRBNALDH1A1MAPK1HSD17B10
Hydrochloric Acid SCHEMBL31554653 0.78 DDB1 (0.61) DDB1CRBNSLC6A2SLC6A4SLC6A3
SCHEMBL30768600 0.76 DDB1 (0.51) DDB1CRBNKHKUSP2CYP2D6
SCHEMBL30769340 0.76 DDB1 (0.51) DDB1CRBNKHKUSP2CYP2D6
SCHEMBL24207007 0.75 CRBN (0.50) DDB1CRBNADRB1ALDH1A1MAPK1
SCHEMBL31306692 0.75 DDB1 (0.56) DDB1CRBNSLC6A4ADRB1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-12-25 US disclosed
EP-4543871-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-04-30 EP disclosed
WO-2024006781-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF ESRRA, ESRRB, ESR2 DDB1 2204/4885CRBN 488/4885SLC6A2 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.